JP2010527980A - 代謝障害を治療するための二環状アリールおよびヘテロアリール化合物 - Google Patents

代謝障害を治療するための二環状アリールおよびヘテロアリール化合物 Download PDF

Info

Publication number
JP2010527980A
JP2010527980A JP2010508908A JP2010508908A JP2010527980A JP 2010527980 A JP2010527980 A JP 2010527980A JP 2010508908 A JP2010508908 A JP 2010508908A JP 2010508908 A JP2010508908 A JP 2010508908A JP 2010527980 A JP2010527980 A JP 2010527980A
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
formula
aryl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010508908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527980A5 (OSRAM
Inventor
ジェイソン・ブロクサム
スチュアート・エドワード・ブラッドリー
トム・バンクシア・ドゥプリー
ピーター・ティモシー・フライ
パトリック・エリック・ハンラハン
トーマス・マーティン・クルル
マーティン・ジェイムズ・プロクター
コリン・ピーター・サムブロック−スミス
カレン・レスリー・スコフィールド
ドナルド・スマイス
アラン・ジョン・ウィリアム・スチュアート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709789A external-priority patent/GB0709789D0/en
Priority claimed from GB0800454A external-priority patent/GB0800454D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of JP2010527980A publication Critical patent/JP2010527980A/ja
Publication of JP2010527980A5 publication Critical patent/JP2010527980A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010508908A 2007-05-22 2008-05-22 代謝障害を治療するための二環状アリールおよびヘテロアリール化合物 Pending JP2010527980A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0709789A GB0709789D0 (en) 2007-05-22 2007-05-22 Compounds
GB0800454A GB0800454D0 (en) 2008-01-11 2008-01-11 Compounds
PCT/GB2008/050370 WO2008142454A1 (en) 2007-05-22 2008-05-22 Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
JP2010527980A true JP2010527980A (ja) 2010-08-19
JP2010527980A5 JP2010527980A5 (OSRAM) 2011-07-07

Family

ID=39643985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010508908A Pending JP2010527980A (ja) 2007-05-22 2008-05-22 代謝障害を治療するための二環状アリールおよびヘテロアリール化合物

Country Status (4)

Country Link
US (1) US8278442B2 (OSRAM)
EP (1) EP2152671A1 (OSRAM)
JP (1) JP2010527980A (OSRAM)
WO (1) WO2008142454A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526661A (ja) * 2014-08-27 2017-09-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｔａａｒリガンドとしての置換アゼチジン誘導体
JP2018520100A (ja) * 2015-05-20 2018-07-26 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規なアゼチジン誘導体

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527980A (ja) 2007-05-22 2010-08-19 プロシディオン・リミテッド 代謝障害を治療するための二環状アリールおよびヘテロアリール化合物
US8063247B2 (en) * 2007-09-07 2011-11-22 Prosidion Limited Bicyclic aryl and heteroaryl receptor modulators
WO2012090177A2 (en) * 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
IN2014MN00226A (OSRAM) * 2011-07-05 2015-09-25 Lupin Ltd
US10273234B2 (en) * 2012-08-06 2019-04-30 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
CN105764888B (zh) 2013-11-20 2018-04-06 株式会社三和化学研究所 一种新的3‑氮杂双环[3.1.0]己烷衍生物以及其医药用途
CN105330616B (zh) * 2015-12-09 2017-09-26 苏州明锐医药科技有限公司 卡利拉嗪的制备方法
KR20190096949A (ko) * 2016-10-05 2019-08-20 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 소분자 ampk 활성화제
CN106588842A (zh) * 2016-12-05 2017-04-26 天津羲泽润科技有限公司 一种合成7‑甲氧基‑1‑苯并呋喃‑4‑甲醛的方法
US12428378B2 (en) 2019-09-10 2025-09-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and materials for increasing level of phosphorylated AMPK protein
WO2023165874A1 (en) * 2022-03-01 2023-09-07 Syngenta Crop Protection Ag Pyrimidinyl-oxy-quinoline based herbicidal compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080968A1 (en) * 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
US20060217372A1 (en) * 2002-09-19 2006-09-28 Maria-Jesus Blanco-Pillado Diaryl ethers as opioid receptor antagonist

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225080B1 (en) * 1992-03-23 2001-05-01 George R. Uhl Mu-subtype opioid receptor
US6235496B1 (en) 1993-03-08 2001-05-22 Advanced Research & Technology Institute Nucleic acid encoding mammalian mu opioid receptor
US5658783A (en) * 1993-11-08 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Mammalian methadone-specific opioid receptor gene and uses
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
ATE308522T1 (de) 2002-05-30 2005-11-15 Lilly Co Eli Opioidrezeptorantagonisten
MXPA05009367A (es) 2003-03-07 2005-11-04 Lilly Co Eli Antagonistas del receptor opioide.
BRPI0417156A (pt) 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
WO2005066164A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Opioid receptor antagonists
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
ES2308471T3 (es) 2004-03-12 2008-12-01 Eli Lilly And Company Antagonistas de receptores de opioides.
ATE545413T1 (de) 2004-03-15 2012-03-15 Lilly Co Eli Antagonisten des opioidrezeptors
JP2007529523A (ja) 2004-03-15 2007-10-25 イーライ リリー アンド カンパニー 肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物
WO2007047397A2 (en) 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors
JP2010500372A (ja) 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
CN102516115B (zh) 2006-08-09 2016-05-11 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物
CN101511808A (zh) 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
EP2084127A1 (en) 2006-11-13 2009-08-05 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
JP2010527980A (ja) 2007-05-22 2010-08-19 プロシディオン・リミテッド 代謝障害を治療するための二環状アリールおよびヘテロアリール化合物
US20100113512A1 (en) * 2008-10-30 2010-05-06 Diane Michele Ignar Method of treatment using novel antagonists or inverse agonists at opioid receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217372A1 (en) * 2002-09-19 2006-09-28 Maria-Jesus Blanco-Pillado Diaryl ethers as opioid receptor antagonist
WO2004080968A1 (en) * 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526661A (ja) * 2014-08-27 2017-09-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｔａａｒリガンドとしての置換アゼチジン誘導体
JP2018520100A (ja) * 2015-05-20 2018-07-26 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規なアゼチジン誘導体

Also Published As

Publication number Publication date
US8278442B2 (en) 2012-10-02
WO2008142454A1 (en) 2008-11-27
EP2152671A1 (en) 2010-02-17
US20100173886A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
JP2010527980A (ja) 代謝障害を治療するための二環状アリールおよびヘテロアリール化合物
CN102271682B (zh) 用于治疗疼痛的p2x3受体拮抗剂
US8008327B2 (en) Indazole compounds as CCR1 receptor antagonists
TWI676620B (zh) 離胺酸特異性去甲基酶-１之抑制劑
US9624215B2 (en) Amine derivative or salt thereof
EP1613597B1 (en) 6-substituted nicotinamide derivatives as opioid receptor antagonists
JP4732354B2 (ja) グリシン輸送阻害薬としての二環式［３．１．０］誘導体
TWI491595B (zh) 作為香草類化合物受體之配體之經取代苯基尿素及苯基醯胺
US20110009421A1 (en) Compound having 6-membered aromatic ring
JP5542946B2 (ja) Ｃｃｒ１受容体アンタゴニストとしてのインダゾール及びピラゾロピリジン化合物
JP2005534715A (ja) カンナビノイドレセプタ配位子
EP1699783B1 (en) Opioid receptor antagonists
MX2008016546A (es) Preparación y aplicación en terapéutica de derivados de imidazo [1,2-a] piridina-2-carboxamidas.
JP2007504229A (ja) 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
CZ189894A3 (en) Bicyclic compounds containing nitrogen and pharmaceutical compositions containing thereof
JP2017533215A (ja) ヒストンリジン脱メチル化触媒活性を調節するための新規ピリドピリミジノン化合物
JP2010500332A (ja) ５，６−ビスアリール−２−ピリジン−カルボキサミド誘導体、これらの調製およびウロテンシンｉｉ受容体アンタゴニストとしてのこれらの治療における使用
JP2007514638A (ja) ジフェニルピリジン誘導体、その製造法および治療用途
KR20130122531A (ko) Ｍｇｌｕｒ５ 양성 알로스테릭 조절물로서 치환된 ６­메틸니코틴아미드
JP2004534082A (ja) グリシン輸送阻害剤としての置換芳香族エーテル
KR20210022646A (ko) 시아노트리아졸 화합물 및 이의 용도
JP6154007B2 (ja) 糖尿病の治療に有用なイミダゾピリジン誘導体
TW201206910A (en) Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
JP2011508758A (ja) Ｎ−フェニルイミダゾ［１，２−α］ピリジン−２−カルボキサミド誘導体、これらの調製およびこれらの治療用途
JP2009179562A (ja) グリシントランスポーター阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140128